A simple Risk-Based Strategy for Hepatitis C virus Screening Among Incarcerated People in a Low- to Middle-Income Setting

Abstract Background: Hepatitis C virus (HCV) is among the highest priority diseases in custodial settings; however, the diagnosis remains suboptimal among people in custody. This study aimed to validate a short survey for identifying people with HCV infection in a provincial prison in Iran.Methods: Between July and December 2018, residents and newly admitted inmates of Gorgan central prison completed a questionnaire, including data on the history of HCV testing, drug use, injecting drug use, sharing injecting equipment, and imprisonment. Participants received rapid HCV antibody testing, followed by venipuncture for RNA testing (antibody-positive only). Each enrollment question (yes/no) was compared with the testing results (positive/negative).Results: Overall, 1892 people completed the questionnaire, including 621 (34%) who were currently on opioid agonist therapy (OAT); 30% of participants had been tested for HCV previously. About 71% had a history of drug use, of whom 13% had ever injected drugs; 56% had ever shared injecting equipment. Prevalence of HCV antibody and RNA was 6.9% (n=130) and 4.8% (n=90), respectively. The antibody prevalence was higher among people on OAT compared to those with no history of OAT (11.4% vs. 4.0%). History of drug use was the most accurate predictor of having a positive HCV antibody (sensitivity: 95.2%, negative predictive value: 98.9%) and RNA testing (sensitivity: 96.7%, negative predictive value: 99.5%). Sensitivity of the drug use question was lowest among people with no OAT history and new inmates (87% and 89%, respectively). Among all participants, sensitivity and negative predictive value of the other questions were low and ranged from 34% to 54% and 94% to 97%, respectively.Conclusions: In resource-limited settings, HCV screening based on having a history of drug use could replace universal screening in prisons to reduce costs. Developing tailored screening strategies together with further cost studies are crucial to address the current HCV epidemic in low- to middle-income countries..

Medienart:	Preprint

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	ResearchSquare.com - (2022) vom: 28. Juli Zur Gesamtaufnahme - year:2022

Sprache:	Englisch

Beteiligte Personen:	Hariri, Sanam [VerfasserIn] Sharafkhah, Maryam [VerfasserIn] Alavi, Maryam [VerfasserIn] Roshandel, Gholamreza [VerfasserIn] Fazel, Abdolreza [VerfasserIn] Amiriani, Taghi [VerfasserIn] Motamed-Gorji, Nazgol [VerfasserIn] Bazazan, Abolfazl [VerfasserIn] Merat, Shahin [VerfasserIn] Poustchi, Hossein [VerfasserIn] Malekzadeh, Reza [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.21203/rs.3.rs-27250/v1

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XRA033921466